Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib with or without Nivolumab in resectable KRAS G12C-mutated NSCLC
NCT05472623Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Pathologic Complete Response Rate at 90 days. Planned start Mar 2023; status: withdrawn.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05472623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472623.